Back to results
US 6,699,885 B2Granted
Substituted benzimidazole dosage forms and methods of using same
AssigneeThe Curators of the University of Missouri
InventorJeffrey O. Phillips
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods, kits, combinations, and compositions for treating gastric acid disorders employing pharmaceutical compositions comprising a proton pump inhibiting agent (PPI) and a buffering agent in a pharmaceutically acceptable carrier.
Claims50
A method of treating a gastric acid related disorder in a subject in need thereof, comprising:
- providing a solid pharmaceutical composition for oral administration to the subject, the composition consisting essentially of:
- (a) a therapeutically effective amount of at least one acid labile, substituted benzimidazole H+, K+-ATPase proton pump inhibitor;
- (b) at least one buffering agent in an amount of about 0.1 mEq to about 2.5 mEq per mg proton pump inhibitor;
- and (c) one or more optional pharmaceutically acceptable excipients;
- and
- orally administering the pharmaceutical composition to the subject,
- wherein upon oral administration of the pharmaceutical composition to the subject, an initial serum concentration of the proton pump inhibitor greater than about 0.1 μg/ml is obtained at any time within about 30 minutes after administration of the composition.
4 more elements
A method of treating a gastric acid related disorder in a subject in need thereof, comprising:
- orally administering to the subject a single dose of a solution or suspension of a pharmaceutical composition, the composition consisting essentially of:
- (a) a therapeutically effective amount of at least one acid labile, substituted benzimidazole H+, K+-ATPase proton pump inhibitor;
- (b) at least one buffering agent in an amount of about 0.1 mEq to about 2.5 mEq per mg proton pump inhibitor;
- and (c) one or more optional pharmaceutically acceptable excipients wherein an initial serum concentration of the proton pump inhibitor greater than about 0.1 μg/ml is obtained at any time within about 30 minutes after administration of the composition, and wherein the administering step does not require further administration of the buffering agent(s) beyond that administered in the single dose.
1 more element
The method of claim 26, wherein the buffering agent comprises sodium bicarbonate.
- 40.The method of claim 39, wherein the sodium bicarbonate is in an amount from about 250 mg to about 4000 mg.
Dependencies are inferred from the claim text.